|
4H-Pyrrolo[3,4-c][1,6]naphthyridin-4-one, 2-(5-benzofuranylsulfonyl)-1,2,3,3a,5,9b-hexahydro-5-methyl-, (3aS,9bS)- Suppliers list
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:AM-1488
CAS:2079895-60-4
Package:50mg/RMB 19420;25mg/RMB 14900;100mg/RMB 24625
|
4H-Pyrrolo[3,4-c][1,6]naphthyridin-4-one, 2-(5-benzofuranylsulfonyl)-1,2,3,3a,5,9b-hexahydro-5-methyl-, (3aS,9bS)- manufacturers
- AM-1488
-
- $2785.00 / 50mg
-
2025-10-27
- CAS:2079895-60-4
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 4H-Pyrrolo[3,4-c][1,6]naphthyridin-4-one, 2-(5-benzofuranylsulfonyl)-1,2,3,3a,5,9b-hexahydro-5-methyl-, (3aS,9bS)- Basic information |
| Product Name: | 4H-Pyrrolo[3,4-c][1,6]naphthyridin-4-one, 2-(5-benzofuranylsulfonyl)-1,2,3,3a,5,9b-hexahydro-5-methyl-, (3aS,9bS)- | | Synonyms: | 4H-Pyrrolo[3,4-c][1,6]naphthyridin-4-one, 2-(5-benzofuranylsulfonyl)-1,2,3,3a,5,9b-hexahydro-5-methyl-, (3aS,9bS)-;AM-1488 | | CAS: | 2079895-60-4 | | MF: | C19H17N3O4S | | MW: | 383.42 | | EINECS: | | | Product Categories: | | | Mol File: | 2079895-60-4.mol | ![4H-Pyrrolo[3,4-c][1,6]naphthyridin-4-one, 2-(5-benzofuranylsulfonyl)-1,2,3,3a,5,9b-hexahydro-5-methyl-, (3aS,9bS)- Structure](CAS/20210305/GIF/2079895-60-4.gif) |
| | 4H-Pyrrolo[3,4-c][1,6]naphthyridin-4-one, 2-(5-benzofuranylsulfonyl)-1,2,3,3a,5,9b-hexahydro-5-methyl-, (3aS,9bS)- Chemical Properties |
| Boiling point | 645.5±65.0 °C(Predicted) | | density | 1.438±0.06 g/cm3(Predicted) | | pka | 6.11±0.20(Predicted) |
| | 4H-Pyrrolo[3,4-c][1,6]naphthyridin-4-one, 2-(5-benzofuranylsulfonyl)-1,2,3,3a,5,9b-hexahydro-5-methyl-, (3aS,9bS)- Usage And Synthesis |
| Description | AM1488 is a Potent and Efficacious Potentiator of Glycine Receptor. | | Uses | AM-1488 is a potent, orally active glycine receptor (GlyR) potentiator (hGlyRα3 EC50=0.45 μM)[1][2]. | | in vivo | AM-1488 (oral gavage; 20 mg/kg; once) treatment significantly reverse mechanical allodynia induced by nerve injury in a mouse model of neuropathic pain, without being confounded by sedation or motor side effects[1]. | Animal Model: | Mouse model of spared nerve injury (SNI)[1] | | Dosage: | 20 mg/kg | | Administration: | Oral gavage; 20 mg/kg; once | | Result: | Produced a significant 94% reversal of tactile allodynia, and the unbound brain concentration was 2.8- and 1.6-fold higher than the mouse GlyRα1 and GlyRα3 EC50 values, respectively. |
| Animal Model: | Naive mice[1] | | Dosage: | 20 mg/kg | | Administration: | Oral gavage; 20 mg/kg; once | | Result: | Showed not significantly different from mice treated with vehicle. |
| | References | [1] Xin Huang, et al. Crystal structures of human glycine receptor α3 bound to a novel class of analgesic potentiators. Nat Struct Mol Biol. 2017 Feb;24(2):108-113. DOI:10.1038/nsmb.3329
[2] Howard Bregman, et al. The Discovery and Hit-to-Lead Optimization of Tricyclic Sulfonamides as Potent and Efficacious Potentiators of Glycine Receptors. J Med Chem. 2017 Feb 9;60(3):1105-1125. DOI:10.1021/acs.jmedchem.6b01496 |
| | 4H-Pyrrolo[3,4-c][1,6]naphthyridin-4-one, 2-(5-benzofuranylsulfonyl)-1,2,3,3a,5,9b-hexahydro-5-methyl-, (3aS,9bS)- Preparation Products And Raw materials |
|